

## Mesoglycan in lower legs teleangiectasia treatment

F. FERRARA G. FERRARA

STUDIO FLEBOLOGICO FERRARA – v. Kuliscioff 25 ACERRA-Na

The Authors describe the rationale of mesoglycan, (a polysaccharide complex composed of heparan sulfate, dermatan sulfate, electrophoretically slow-moving heparin, and variable and minimal quantities of chondroitin sulfate), as lower leg teleangiectasia (with diameter < 0,3 mm) counteracting agent: in fact this high density, high molecular weight molecule can easily and painlessly be injected along or accross the dilated capillaries network, or around dilated veins. Counteracting the micro-venous hypertension and reinforcing the fundamental substance lining around the small vessels. Mesoglycan has a very long half life and it's postinjection local retention produces steady haemodynamic improvement of microcirculation through mesenchyma and interstitial fluids modification and turnover. Costs versus profits, compared with convetional treatments are finally outlined and related to the final outcome.